Advertisement
Telix Pharmaceuticals Lim... (TLX)
Telix Pharmaceuticals Statistics
Share Statistics
Telix Pharmaceuticals has - shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | - |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 31 |
| FTD / Avg. Volume | 0.08% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is null. Telix Pharmaceuticals's PEG ratio is 0.
| PE Ratio | 0 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Telix Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.78, with a Debt / Equity ratio of 1.02.
| Current Ratio | 2.78 |
| Quick Ratio | 2.66 |
| Debt / Equity | 1.02 |
| Debt / EBITDA | 6.28 |
| Debt / FCF | 64.63 |
| Interest Coverage | 2.25 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $- |
| Profits Per Employee | $- |
| Employee Count | undefined |
| Asset Turnover | 0.52 |
| Inventory Turnover | 7.17 |
Taxes
| Income Tax | 6.14M |
| Effective Tax Rate | 10.95% |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 2.49, so Telix Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 2.49 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 17.38 |
| 200-Day Moving Average | null |
| Relative Strength Index (RSI) | 52.94 |
| Average Volume (20 Days) | 37.36K |
Income Statement
In the last 12 months, Telix Pharmaceuticals had revenue of 783.21M and earned 49.92M in profits. Earnings per share was 0.
| Revenue | 783.21M |
| Gross Profit | 509.68M |
| Operating Income | 82.13M |
| Net Income | 49.92M |
| EBITDA | 92.55M |
| EBIT | 92.55M |
| Earnings Per Share (EPS) | 0 |
Balance Sheet
The company has 710.35M in cash and 581.45M in debt, giving a net cash position of 128.9M.
| Cash & Cash Equivalents | 710.35M |
| Total Debt | 581.45M |
| Net Cash | 128.9M |
| Retained Earnings | -212.96M |
| Total Assets | 1.52B |
| Working Capital | 587.65M |
Cash Flow
In the last 12 months, operating cash flow was 0 and capital expenditures -34.03M, giving a free cash flow of 9M.
| Operating Cash Flow | 0 |
| Capital Expenditures | -34.03M |
| Free Cash Flow | 9M |
| FCF Per Share | 0 |
Margins
Gross margin is 65.08%, with operating and profit margins of 10.49% and 6.37%.
| Gross Margin | 65.08% |
| Operating Margin | 10.49% |
| Pretax Margin | 7.16% |
| Profit Margin | 6.37% |
| EBITDA Margin | 11.82% |
| EBIT Margin | 10.49% |
| FCF Margin | 1.15% |
Dividends & Yields
TLX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for TLX is $22, which is 25.6% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $22 |
| Price Target Difference | 25.6% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
Scores
| Altman Z-Score | 4.16 |
| Piotroski F-Score | 1 |